PDF(Pubmed)
Abstract：
UNASSIGNED: Brain metastases from ovarian cancer are extremely rare and have a very poor prognosis. A multimodal approach (surgery combined with radiotherapy and chemotherapy) yields the best results in reducing neurological symptoms and prolonging survival. Unfortunately, not every patient receives a complete multimodal treatment due to their individual factors. Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as a maintenance treatment option for recurrent ovarian cancer. Using PARPi may prolong the overall survival in patients with brain metastases and recurrent ovarian cancer.
UNASSIGNED: We report a case of a female patient with advanced ovarian cancer without any germline or somatic BRCA mutation. After 21 months, after reduction surgery and adjuvant chemotherapy, she was diagnosed with brain metastasis. Due to her physical fitness and economic situation, she did not receive any radiotherapy or chemotherapy but only received surgical debulking of the brain metastasis and niraparib maintenance treatment. Up to now, she has achieved a good treatment response, and the PFS is 29 months.
UNASSIGNED: Based on the response of our patient, PARP inhibitors as a single agent can probably be considered in patients with brain metastasis from ovarian cancer without BRCA mutation who cannot tolerate radiotherapy and chemotherapy.
UNASSIGNED: We report a case of a female patient with advanced ovarian cancer without any germline or somatic BRCA mutation. After 21 months, after reduction surgery and adjuvant chemotherapy, she was diagnosed with brain metastasis. Due to her physical fitness and economic situation, she did not receive any radiotherapy or chemotherapy but only received surgical debulking of the brain metastasis and niraparib maintenance treatment. Up to now, she has achieved a good treatment response, and the PFS is 29 months.
UNASSIGNED: Based on the response of our patient, PARP inhibitors as a single agent can probably be considered in patients with brain metastasis from ovarian cancer without BRCA mutation who cannot tolerate radiotherapy and chemotherapy.
摘要：
未经证实：卵巢癌脑转移极为罕见，预后极差。多模式方法（手术结合放疗和化疗）在减轻神经系统症状和延长生存期方面效果最好。不幸的是,并非每个患者都因其个体因素而接受完整的多模式治疗。聚（ADP-核糖）聚合酶（PARP）抑制剂已成为复发性卵巢癌的维持治疗选择。使用PARPi可延长脑转移和复发性卵巢癌患者的总生存期。
未经证实：我们报告一例女性晚期卵巢癌患者，无任何种系或体细胞BRCA突变。21个月后,复位手术和辅助化疗后，她被诊断为脑转移。由于她的身体素质和经济状况，她没有接受任何放疗或化疗，只接受了脑转移瘤的手术切除和尼拉帕尼维持治疗。到目前为止,她取得了良好的治疗反应，PFS是29个月。
未经评估：根据我们患者的反应，对于无BRCA突变且不能耐受放疗和化疗的卵巢癌脑转移患者，可考虑使用PARP抑制剂作为单一药物。
未经证实：我们报告一例女性晚期卵巢癌患者，无任何种系或体细胞BRCA突变。21个月后,复位手术和辅助化疗后，她被诊断为脑转移。由于她的身体素质和经济状况，她没有接受任何放疗或化疗，只接受了脑转移瘤的手术切除和尼拉帕尼维持治疗。到目前为止,她取得了良好的治疗反应，PFS是29个月。
未经评估：根据我们患者的反应，对于无BRCA突变且不能耐受放疗和化疗的卵巢癌脑转移患者，可考虑使用PARP抑制剂作为单一药物。
